Neurocrine Biosciences, Inc. (NBIX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
"main_header": {
"sid": 1158064,
"name": "Neurocrine Biosciences, Inc.",
"stock_name": "Neurocrine Biosciences, Inc.",
"full_name": "Neurocrine Biosciences, Inc.",
"name_url": "stocks-analysis/neurocrine-biosciences-inc",
"exchange": 210,
"exchangecode": "NAS",
"country_id": 2,
"currency": "USD",
"cmp": "154.22",
"chg": 1.74,
"chgp": "1.14%",
"dir": 1,
"prev_price": "152.48",
"mcapval": "14,262.30",
"mcap": "Small Cap",
"scripcode": "",
"symbol": "",
"ind_name": "Pharmaceuticals & Biotechnology",
"ind_code": 2305,
"indexname": "S&P 500",
"isin": "US64125C1099",
"curr_date": "Dec 04",
"curr_time": "",
"bse_nse_vol": "1.2 M",
"exc_status": "Active",
"traded_date": "Dec 04, 2025",
"traded_date_str": "2025 12 04",
"score": "",
"scoreText": "",
"Live": 0,
"market_time": 0,
"is_blur": 1,
"is_blur_class": "blur-register-score-header",
"is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/neurocrine-biosciences-inc-1158064-210&utm_source=Spage_Header_Score",
"mojoone": {
"ismore": 0
}
},
"news": {
"results": [
{
"title": "Is Neurocrine Biosciences, Inc. overvalued or undervalued?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-overvalued-or-undervalued-3728350",
"imagepath": "",
"date": "2025-11-25 11:14:44",
"description": "As of 21 November 2025, the valuation grade for Neurocrine Biosciences, Inc. has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 35, an EV to EBITDA ratio of 21.72, and a robust ROCE of 30.61%. In comparison to peers, Neurocrine's P/E ratio is more favorable than Viatris, Inc., which has a P/E of 44.86, while Walgreens Boots Alliance, Inc. shows a negative P/E, highlighting Neurocrine's relative strength in the market.\n\nDespite recent stock performance showing a 1-year return of 12.42% compared to the S&P 500's 11.00%, the longer-term picture reveals a significant underperformance over 3 years and 5 years, with returns of 18.73% and 47.43%, respectively, against the S&P 500's 67.17% and 85.61%. This suggests that while Neurocrine is currently attractive, it has lagged behind broader market returns over th..."
},
{
"title": "Is Neurocrine Biosciences, Inc. overvalued or undervalued?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-overvalued-or-undervalued-3723339",
"imagepath": "",
"date": "2025-11-23 11:10:18",
"description": "As of 21 November 2025, the valuation grade for Neurocrine Biosciences, Inc. has moved from fair to attractive, indicating a more favorable assessment of its stock. The company appears to be undervalued, supported by a P/E ratio of 35, an EV to EBITDA of 21.72, and a robust ROCE of 30.61%. In comparison, Viatris, Inc. has a higher P/E of 44.86, while Walgreens Boots Alliance, Inc. shows a negative P/E, highlighting Neurocrine's relative valuation strength within its peer group.\n\nDespite recent underperformance against the S&P 500, with a 3-year return of 19.88% compared to the index's 67.17%, the company's strong fundamentals suggest it may be positioned for future growth. Overall, Neurocrine's attractive valuation metrics and strong return on capital indicate it is a compelling investment opportunity...."
},
{
"title": "Is Neurocrine Biosciences, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-technically-bullish-or-bearish-3673544",
"imagepath": "",
"date": "2025-11-05 11:19:14",
"description": "As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD supports this with a bullish signal. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating potential upward movement. Overall, the stock has underperformed the S&P 500 in the year-to-date and three-year periods, but has shown a positive return over the past month. The current technical stance is bullish, but with some caution due to mixed signals in shorter time frames...."
},
{
"title": "Is Neurocrine Biosciences, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-technically-bullish-or-bearish-3670740",
"imagepath": "",
"date": "2025-11-04 11:30:42",
"description": "As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD is also bullish. However, the weekly MACD and KST are mildly bearish, suggesting some mixed signals in the shorter term. The Bollinger Bands show a mildly bullish trend in both weekly and monthly time frames. Overall, the stock is currently bullish, but the strength is tempered by the mixed indicators on the weekly charts.\n\nIn terms of performance, Neurocrine has underperformed the S&P 500 over the year and three-year periods, with returns of 16.16% and 14.38% respectively, compared to the S&P 500's 19.89% and 76.66%...."
},
{
"title": "Is Neurocrine Biosciences, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-technically-bullish-or-bearish-3666326",
"imagepath": "",
"date": "2025-11-03 11:29:52",
"description": "As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages are bullish, and both the monthly Bollinger Bands and OBV indicators are also bullish, supporting the positive stance. However, the weekly MACD and KST indicators are mildly bearish, indicating some caution in the short term. \n\nIn terms of performance, the stock has underperformed the S&P 500 on a year-to-date basis (4.92% vs. 16.30%) and over three years (24.40% vs. 76.66%), but it has shown a strong one-year return of 19.07% compared to the S&P 500's 19.89%. Overall, the current technical stance is bullish, albeit with some mixed signals in the shorter time frames...."
},
{
"title": "Is Neurocrine Biosciences, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-technically-bullish-or-bearish-3664444",
"imagepath": "",
"date": "2025-11-02 11:15:57",
"description": "As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly Bollinger Bands and MACD also support a bullish outlook. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. The On-Balance Volume is bullish for both weekly and monthly periods, reinforcing the overall bullish sentiment. \n\nIn terms of performance, the stock has underperformed the S&P 500 year-to-date and over the last three and five years, with returns of 4.92% compared to the S&P 500's 16.30%, and 24.40% versus 76.66%, respectively. Overall, the current technical stance is bullish, but with some caution due to mixed signals in the shorter time frames...."
},
{
"title": "Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance",
"link": "https://www.marketsmojo.com/news/stocks-in-action/neurocrine-biosciences-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-strong-stock-performance-3652043",
"imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NeurocrineBiosc_technicaldot_3652043.png",
"date": "2025-10-28 15:28:37",
"description": "Neurocrine Biosciences, Inc. has recently experienced a revision in its evaluation amid fluctuating market conditions. The stock has demonstrated strong performance metrics, outpacing the S&P 500 over various time frames. Technical indicators show a predominantly bullish sentiment, although some mixed signals are present in the short term."
},
{
"title": "Is Neurocrine Biosciences, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-technically-bullish-or-bearish-3651300",
"imagepath": "",
"date": "2025-10-28 11:40:00",
"description": "As of 24 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly charts, and Bollinger Bands also indicate bullish momentum on both time frames. Daily moving averages are bullish as well. However, the KST shows a mildly bearish signal on the weekly and monthly, and Dow Theory presents a mixed view with a mildly bearish weekly signal but a mildly bullish monthly signal. \n\nIn terms of performance, Neurocrine has outperformed the S&P 500 over the past week and year, with returns of 2.79% compared to 1.92% for the S&P 500 in the last week, and 24.65% versus 16.90% over the past year. However, it has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the bullish indicators suggest a positiv..."
},
{
"title": "Is Neurocrine Biosciences, Inc. technically bullish or bearish?",
"link": "https://www.marketsmojo.com/news/stocks-in-action/is-neurocrine-biosciences-inc-technically-bullish-or-bearish-3647753",
"imagepath": "",
"date": "2025-10-27 11:51:06",
"description": "As of 24 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend in both time frames. Daily moving averages are bullish, while the On-Balance Volume (OBV) is bullish on both weekly and monthly scales. However, the KST shows a mildly bearish signal on both weekly and monthly, and Dow Theory indicates a mildly bearish stance on the weekly but a mildly bullish stance on the monthly.\n\nIn terms of performance, Neurocrine has outperformed the S&P 500 over the past week with a return of 2.79% compared to the S&P 500's 1.92%, but it has underperformed over the past month, year-to-date, and over the longer terms of 3, 5, and 10 years...."
}
],
"total": 28,
"sid": "1158064",
"stock_news_url": "https://www.marketsmojo.com/news/neurocrine-biosciences-inc-1158064"
},
"announcements": "",
"corporate_actions": {
"msg": "No corporate action Found"
}
}

News and Views

Is Neurocrine Biosciences, Inc. overvalued or undervalued?

2025-11-25 11:14:44

As of 21 November 2025, the valuation grade for Neurocrine Biosciences, Inc. has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 35, an EV to EBITDA ratio of 21.72, and a robust ROCE of 30.61%. In comparison to peers, Neurocrine's P/E ratio is more favorable than Viatris, Inc., which has a P/E of 44.86, while Walgreens Boots Alliance, Inc. shows a negative P/E, highlighting Neurocrine's relative strength in the market. Despite recent stock performance showing a 1-year return of 12.42% compared to the S&P 500's 11.00%, the longer-term picture reveals a significant underperformance over 3 years and 5 years, with returns of 18.73% and 47.43%, respectively, against the S&P 500's 67.17% and 85.61%. This suggests that while Neurocrine is currently attractive, it has lagged behind broader market returns over th...

Is Neurocrine Biosciences, Inc. overvalued or undervalued?

2025-11-23 11:10:18

As of 21 November 2025, the valuation grade for Neurocrine Biosciences, Inc. has moved from fair to attractive, indicating a more favorable assessment of its stock. The company appears to be undervalued, supported by a P/E ratio of 35, an EV to EBITDA of 21.72, and a robust ROCE of 30.61%. In comparison, Viatris, Inc. has a higher P/E of 44.86, while Walgreens Boots Alliance, Inc. shows a negative P/E, highlighting Neurocrine's relative valuation strength within its peer group. Despite recent underperformance against the S&P 500, with a 3-year return of 19.88% compared to the index's 67.17%, the company's strong fundamentals suggest it may be positioned for future growth. Overall, Neurocrine's attractive valuation metrics and strong return on capital indicate it is a compelling investment opportunity....

Is Neurocrine Biosciences, Inc. technically bullish or bearish?

2025-11-05 11:19:14

As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD supports this with a bullish signal. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating potential upward movement. Overall, the stock has underperformed the S&P 500 in the year-to-date and three-year periods, but has shown a positive return over the past month. The current technical stance is bullish, but with some caution due to mixed signals in shorter time frames....

Is Neurocrine Biosciences, Inc. technically bullish or bearish?

2025-11-04 11:30:42

As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD is also bullish. However, the weekly MACD and KST are mildly bearish, suggesting some mixed signals in the shorter term. The Bollinger Bands show a mildly bullish trend in both weekly and monthly time frames. Overall, the stock is currently bullish, but the strength is tempered by the mixed indicators on the weekly charts. In terms of performance, Neurocrine has underperformed the S&P 500 over the year and three-year periods, with returns of 16.16% and 14.38% respectively, compared to the S&P 500's 19.89% and 76.66%....

Is Neurocrine Biosciences, Inc. technically bullish or bearish?

2025-11-03 11:29:52

As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages are bullish, and both the monthly Bollinger Bands and OBV indicators are also bullish, supporting the positive stance. However, the weekly MACD and KST indicators are mildly bearish, indicating some caution in the short term. In terms of performance, the stock has underperformed the S&P 500 on a year-to-date basis (4.92% vs. 16.30%) and over three years (24.40% vs. 76.66%), but it has shown a strong one-year return of 19.07% compared to the S&P 500's 19.89%. Overall, the current technical stance is bullish, albeit with some mixed signals in the shorter time frames....

Is Neurocrine Biosciences, Inc. technically bullish or bearish?

2025-11-02 11:15:57

As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly Bollinger Bands and MACD also support a bullish outlook. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. The On-Balance Volume is bullish for both weekly and monthly periods, reinforcing the overall bullish sentiment. In terms of performance, the stock has underperformed the S&P 500 year-to-date and over the last three and five years, with returns of 4.92% compared to the S&P 500's 16.30%, and 24.40% versus 76.66%, respectively. Overall, the current technical stance is bullish, but with some caution due to mixed signals in the shorter time frames....

Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-28 15:28:37

Neurocrine Biosciences, Inc. has recently experienced a revision in its evaluation amid fluctuating market conditions. The stock has demonstrated strong performance metrics, outpacing the S&P 500 over various time frames. Technical indicators show a predominantly bullish sentiment, although some mixed signals are present in the short term.

Is Neurocrine Biosciences, Inc. technically bullish or bearish?

2025-10-28 11:40:00

As of 24 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly charts, and Bollinger Bands also indicate bullish momentum on both time frames. Daily moving averages are bullish as well. However, the KST shows a mildly bearish signal on the weekly and monthly, and Dow Theory presents a mixed view with a mildly bearish weekly signal but a mildly bullish monthly signal. In terms of performance, Neurocrine has outperformed the S&P 500 over the past week and year, with returns of 2.79% compared to 1.92% for the S&P 500 in the last week, and 24.65% versus 16.90% over the past year. However, it has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the bullish indicators suggest a positiv...

Is Neurocrine Biosciences, Inc. technically bullish or bearish?

2025-10-27 11:51:06

As of 24 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend in both time frames. Daily moving averages are bullish, while the On-Balance Volume (OBV) is bullish on both weekly and monthly scales. However, the KST shows a mildly bearish signal on both weekly and monthly, and Dow Theory indicates a mildly bearish stance on the weekly but a mildly bullish stance on the monthly. In terms of performance, Neurocrine has outperformed the S&P 500 over the past week with a return of 2.79% compared to the S&P 500's 1.92%, but it has underperformed over the past month, year-to-date, and over the longer terms of 3, 5, and 10 years....

View All News